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Abstract
Background: Exposures during the prenatal period may have lasting effects on maternal and child health
outcomes. To better understand the effects of the in utero environment on children’s short- and long-term health,
large representative pregnancy cohorts with comprehensive information on a broad range of environmental
influences (including biological and behavioral) and the ability to link to prenatal, child and maternal health
outcomes are needed. The Research Program on Genes, Environment and Health (RPGEH) pregnancy cohort at
Kaiser Permanente Northern California (KPNC) was established to create a resource for conducting research to
better understand factors influencing women’s and children’s health. Recruitment is integrated into routine clinical
prenatal care at KPNC, an integrated health care delivery system. We detail the study design, data collection, and
methodologies for establishing this cohort. We also describe the baseline characteristics and the cohort’s
representativeness of the underlying pregnant population in KPNC.
Methods: While recruitment is ongoing, as of October 2014, the RPGEH pregnancy cohort included 16,977
pregnancies (53 % from racial and ethnic minorities). RPGEH pregnancy cohort participants consented to have
blood samples obtained in the first trimester (mean gestational age 9.1 weeks ± 4.2 SD) and second trimester
(mean gestational age 18.1 weeks ± 5.5 SD) to be stored for future use. Women were invited to complete a
questionnaire on health history and lifestyle. Information on women’s clinical and health assessments before, during
and after pregnancy and women and children’s health outcomes are available in the health system’s electronic
health records, which also allows long-term follow-up.
Discussion: This large, racially- and ethnically-diverse cohort of pregnancies with prenatal biospecimens and clinical
data is a valuable resource for future studies on in utero environmental exposures and maternal and child perinatal
and long term health outcomes. The baseline characteristics of RPGEH Pregnancy Cohort demonstrate that it is
highly representative of the underlying population living in the broader community in Northern California.
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Background
Exposures before and during pregnancy contribute to
the immediate and future health outcomes of both
women and their children. Emerging evidence supports
the notion that the prenatal period is a critical devel-
opmental window during which in utero exposures
may have lasting effects on a child’s future health [1,
2]. Biological programming [3] occurs during fetal life
in response to in utero exposure to nutrient substrates,
hormones, growth factors, cytokines, environmental
conditions or toxins, and other exposures. Evidence
also shows that women who develop pregnancy com-
plications are at increased risk of developing chronic
diseases later in life [4–7]. However, the mechanisms
underlying many of these findings remain unclear, and
further research is needed to advance our understand-
ing of how the in utero environment impacts the
short- and long-term health of both the woman and
her child.
Large studies with multiple measurements of bio-
markers during pregnancy are needed to better measure
perinatal exposures and to understand the etiologically
relevant period of the effects of exposures on perinatal
outcomes. To fully understand how the in utero envir-
onment influences the short- and long-term health of
women and their children, large representative study
populations with comprehensive information on a broad
range of factors, including biomarkers, medical condi-
tions, medications, nutrition, physical activity and envir-
onmental exposures, are needed.
The Kaiser Permanente Northern California (KPNC)
Research Program on Genes, Environment, and Health
(RPGEH) has established a large pregnancy cohort that
integrates biospecimens with rich and accurate clinical
and health data available from the electronic health
record (EHR), creating a unique resource available to
advance research on women’s and children’s health.
The establishment of this pregnancy cohort within an
integrated health care delivery system with an EHR has
the additional advantage of enabling accurate assess-
ment of short- and long-term maternal and child health
outcomes and the rapid translation of clinically mean-
ingful findings into clinical practice. This report de-
scribes the design and methods used to establish this
pregnancy cohort and its biorepository in KPNC. We
present preliminary data on the baseline characteristics
of the cohort to demonstrate its racial-ethnic diversity
and the prevalence of several perinatal complications of
interest, as well as its representativeness with regard to
the underlying population of pregnancies at KPNC. We
further discuss possible use of this large cohort including
the ability to efficiently follow it prospectively through the




The aim of this project is to establish a large pregnancy
cohort that integrates biospecimens with rich and accurate
clinical and health data to create a resource to advance
scientific research on women’s and children’s health. The
pregnancy cohort is able to be linked to short- and long-
term maternal and child health outcomes to facilitate the
rapid translation of clinically meaningful findings into
clinical practice.
Design
The KPNC Division of Research started the Research
Program on Genes, Environment and Health (RPGEH)
in 2007 to develop a genetic epidemiology population
resource which integrates data from multiple sources
from consenting KPNC adult members, including bios-
pecimens, clinical data from the EHR, lifestyle and risk
factor data from surveys, and environmental exposure
data from both laboratory and geographic information
systems. One component of the RPGEH is the RPGEH
Pregnancy Cohort.
Establishment of RPGEH pregnancy cohort
The Division of Research worked closely with KPNC
clinical partners to develop facility-based recruitment
procedures and laboratory blood processing workflows
that could be easily integrated as part of routine prenatal
medical care. The entire recruitment process was de-
signed to become an integrated and routine part of the
clinical prenatal intake process. To avoid disruption of
clinical workflows, all RPGEH program-related processes
(e.g., questions from patients, and follow-up) are han-
dled by research staff. The recruitment and biospecimen
collection protocol processes are described below.
Study setting
KPNC provides integrated health care to over 3.6 million
members through 7,000 physicians, > 240 medical office
buildings and 22 hospitals. The KPNC service area spans
14 counties of the greater Bay Area, as well as the
California Central Valley from Sacramento to Fresno
and includes urban and rural areas. The population is
highly representative of the demographic characteristics
of the entire population from this geographic area [8].
The membership is racially and socio-economically di-
verse. KPNC is vertically integrated such that all care is
provided in a closed system and documented in an EHR.
The EHR are clinical records, not claims data, and thus
are robust with regard to data quality and completeness.
The membership of reproductive-aged women (15–44)
includes women with KP commercial insurance (varying
copays, varying deductible levels), MediCal, and other
California state subsidized programs. Within KPNC,
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there are 16 delivery hospitals and approximately 38,000
pregnancies each year.
Recruitment of participants
The RPGEH Pregnancy Cohort recruitment began in
February 2010 at the KPNC Walnut Creek outpatient
medical facility. Recruitment gradually expanded to
cover almost the entire KPNC service area. Figure 1
shows the geographical locations of RPGEH pregnancy
cohort members in an area of over 28,000 square miles,
an area slightly larger than South Carolina. Clinical staff,
such as medical assistants and nurses at the Obstetrics
and Gynecology department, routinely gives a RPGEH
pregnancy cohort flyer with frequently asked questions
and a consent form to women at the initial prenatal visit.
They also briefly describe the RPGEH Pregnancy Cohort
and ask women if they would like to participate. If the
woman agrees to participate and signs the consent form,
the clinic staff places the research blood draw order in
the woman’s EHR.
Biospecimen collection and storage process
Women who consent have blood drawn for research pur-
poses into one 8.5 mL serum separator tube (SST) tube
and one 6.0 mL ethylenediaminetetraacetic Acid (EDTA)
tube at the same time as the clinically ordered blood tests
at her local KPNC laboratory at two times during their
pregnancy: in the first trimester during a standard first
trimester panel or genetic screening (~10–13 weeks,
6 days) and during the second trimester either along with
standard genetic screening (~15–20 weeks) or with the
gestational diabetes screening (~24–28 weeks). The blood
tubes are couriered as part of the normal KPNC labora-
tory system to the Regional Laboratory, where they are
transferred to the RPGEH Biorepository (see description
below) and further processing occurs.
The RPGEH Research Biorepository
The RPGEH Biorepository is a state-of-the-art research
biorepository and staffed with research laboratory
personnel who are responsible for maintaining the la-
boratory space, checking in, processing and storing
samples, and retrieving aliquots for studies. Equipment
includes an ABF 500 automated blood fractionation
robot unit, an RTS A4 temperature and humidity con-
trolled robotic ambient storage unit for archiving DNA
using Biomatrica DNA stable storage medium, and a
walk-in−80 ° C freezer. A custom developed Laboratory
Information Management System (LIMS) tracks speci-
mens at each step and is linkable to RPGEH operations
and clinical information databases.
Once at the Biorepository, serum from the SST is ali-
quotted into 4, 0.8 mL cryovials. The EDTA tube is centri-
fuged and plasma is aliquoted into 2, 0.8 mL cryovials,
while 1.0 mL of buffy coat is aspirated and placed in a
cryovial. All cryovials are stored at−80 °C.
Clinical data
Information on participants in the Pregnancy Cohort
is obtained from several sources of rich clinical data
(resources are described below).
Information obtained from the EHR during the first
prenatal visit
As part of routine prenatal care, all pregnant women
complete a prenatal questionnaire during the first tri-
mester or shortly after the pregnancy is clinically con-
firmed. This questionnaire includes questions on parity,
gravidity, prior delivery and birth history, reproductive
history, menstrual history, prior medical history, social
circumstances (e.g., stress, domestic violence, etc.), and
an Adult Outcomes Questionnaire (AOQ) which in-
cludes the PHQ-9 [9, 10] depression screener and the
Generalized Anxiety Disorder scale (GAD-2) [11] as well
as functioning items. The information from the Prenatal
Questionnaire is recorded in the KPNC EHR for access
to extensive health and reproductive history on the co-
hort. Several other sources of pre-pregnancy information
are available in the EHR including pre-pregnancy body
mass index (BMI) if a woman had been a KPNC mem-
ber prior to conception.
Early start substance use data
In addition to the Prenatal Questionnaire, a self-
administered Early Start Program Prenatal Substance
Use Screening Questionnaire is completed at entry into
prenatal care. Early Start is an integrated prenatal pro-
gram to intervene when a pregnant woman reports
alcohol, tobacco and other drug use during pregnancy
[12]. The questionnaire asks about substance use before
pregnancy and since pregnancy began, including alco-
hol, smoking, and prescription drug use.
Clinical data available in KPNC EHR
KPNC maintains complete databases that capture all
encounters including hospitalizations, outpatient visits,
radiology/imaging, laboratory tests, and prescription
medications and combines these data for presentation
to clinicians as part of the EHR. Data captured in these
databases include inpatient and outpatient diagnostic
information, imaging reports, laboratory tests and re-
sults, pharmacy dispenses including dosages and days
of supply, and surgery outcomes, among others. All
vital signs including weight and height, blood pressure
and physical activity are recorded in the EHR. As noted
above, these data are clinical information maintained in
an EHR and are not claims data, and enable the de-
tailed examination of diagnoses and treatments before,
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Fig. 1 Geographic locations of Kaiser Permanente Northern California RPGEH Pregnancy Cohort members
Hedderson et al. BMC Pregnancy and Childbirth  (2016) 16:381 Page 4 of 10
during and after pregnancy. In addition, when an infant
is born, he/she is issued a unique medical record num-
ber (MRN) that is used for all care associated with the
infant. It is linkable to the mother’s unique MRN that
allow identification of the mother-infant pair. This al-
lows us to also link to the women’s infants and examine
infant growth and outcomes at birth and during child-
hood, along with other health outcomes, including the
mother’s outcomes.
RPGEH pregnancy cohort questionnaire
To obtain more detailed information not captured in the
HER, each participant is invited to complete the RPGEH
Pregnancy Cohort questionnaire. The RPGEH question-
naire ascertains information about a variety of socio-
demographic, lifestyle and environmental factors not rou-
tinely captured in the EHR, including diet, physical activ-
ity, multivitamin use and self-reported health history
before and during the study pregnancy (Additional file 1).
Environmental exposure data
Over 98 % of the RPGEH pregnancy cohort has been
successfully geocoded and can be linked to contextual or
environmental data, including spatiotemporal data that
exist in public access databases. These data come from
commercial sources, non-profit agencies, and local, re-
gional, state and national government agencies. Data from
these various sources are being incorporated into a KPNC
geographic information system (GIS) database using Arc-
GIS software (Redlands, CA). The database will include
data on retail food outlets, green space, infrastructure
(roads, educational facilities, health delivery centers, and
public assistance facilities), traffic density, air pollution,
pesticide use, toxic sites, toxic release inventories, and
other factors. Other relevant information, currently lo-
cated at other agencies but available for linkage, includes
water quality, centers of social congregation (e.g., religious
or spiritual institutions, senior centers, youth activity cen-
ters, etc.), and crime data. California has some of the most
complete publically available geospatial data across these
environmental factors anywhere in the world.
Below we describe the sources used for determining the
clinical outcomes of the RPGEH Pregnancy Cohort partic-
ipants and non-participants for this preliminary report.
Clinical outcomes during pregnancy/in utero exposure to
maternal metabolism
Women’s body mass index and gestational weight gain
Through the EHR we are able to capture a woman’s body
mass index prior to pregnancy as well her gestational
weight gain trajectory and total gestational weight gain,
allowing us to assess possible determinants of gestational
weight gain, as well as to define the sequelae of in utero
exposure to maternal obesity and excessive gestational
weight gain (i.e., over nutrition) or inadequate gestational
weight gain (i.e., undernutrition) in relation to the current
Institute of Medicine guidelines [13] on child health.
Pregestational diabetes and gestational diabetes mellitus
(GDM) and impaired glucose tolerance
Pregestational diabetes is obtained from the KPNC Dia-
betes Registry [14] and GDM is obtained from the KPNC
pregnancy glucose tolerance and GDM Registry [15].
These registries allow for the identification of GDM based
on objective glucose measurement defined according to
laboratory glucose values meeting the Carpenter and
Coustan diagnostic criteria [16].
Preeclampsia/Hypertensive disorder of pregnancy
Preeclampsia and hypertensive disorders of pregnancy
were also obtained from the EHR and were defined accord-
ing to the following ICD-9 codes: pre-existing hypertension
642.0–642.2, gestational hypertension 642.3, preeclampsia
or eclampsia 642.4–642.7. The validity of these ICD-9
codes to diagnose hypertensive disorders of pregnancy has
previously been reported [17].
Clinical outcomes at birth
Preterm birth
Gestational age is based on the estimated date of delivery
recorded in the EHR, which is determined by the woman’s
self-reported last menstrual period (LMP), or by first
trimester ultrasound if different from the LMP-based cal-
culation by more than 1 week. Preterm birth was defined
as birth at <37 weeks’ gestation. We also examined the
degree of preterm birth using the following definitions:
extreme preterm (<28 weeks’ completed gestation), severe
preterm (28–31 weeks' completed gestation), moderate
preterm (32–33 weeks' completed gestation) and late pre-
term (34–36 weeks' completed gestation) [18].
Infant size for gestational age
Infant birthweight was obtained from the EHR. Large
for gestational age was defined as birthweight >90th per-
centile and small for gestational age was defined as
birthweight <10th percentile for the underlying KPNC
population’s race-ethnicity and gestational age–specific
birthweight distribution [19].
Cesarean delivery
Cesarean delivery information was obtained from the
KPNC neonatal and infant cohort [20] and is defined ac-
cording to ICD-9 codes 654.2× for delivery mode re-
corded in the EHR.
Recruitment to date and prevalence of outcomes of interest
Between February 2010 and October 2014, pregnant
members of KPNC aged 18 or older who initiated
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prenatal care at a KPNC medical facility participating in
the pregnancy cohort were invited to participate in the
RPGEH pregnancy cohort. Among the 93,409 pregnan-
cies occurring at medical facilities participating in the
RPGEH pregnancy cohort during this initial recruitment
period, 16,977 RPGEH pregnancy cohort consent forms
were received, which represents a participation rate of
18.2 %. Compared to non-participants, women who
participated in the pregnancy cohort were similar in age,
but were more likely to have initiated prenatal care in
the first trimester and to be non-Hispanic white and
were slightly less likely to be Asian (Table 1). RPGEH
pregnancy cohort participants were KPNC members for
an average of 10 years before their pregnancy (Table 1).
Among the 16,977 RPGEH pregnancy cohort partici-
pants who delivered a liveborn infant at the time of this
writing, 93.2 % had a first trimester blood draw (mean
gestational age: 9.1 weeks +/−4.2 SD) and 80.5 % had a
second trimester blood draw (mean gestational age:
18.1 weeks +/−5.5 SD) and 77.6 % had blood drawn in
both trimesters.
Of the 93,409 pregnancies initially identified, 80,086
(84 %) delivered an infant in Kaiser Permanente Northern
California. Of the pregnancies not resulting in livebirths,
5.7 % were due to pregnancy loss, 4.6 % no longer had
Kaiser medical coverage, and 4.0 % delivered outside of
Kaiser. Among the deliveries in Kaiser Permanente
Northern California, the prevalence of preterm birth
(<37 weeks), cesarean delivery, small for gestational age,
large for gestational age, macrosomia, preeclampsia, GDM
and NICU admissions was similar between RPGEH preg-
nancy cohort participants and non-participants (none of
these outcomes differed by more than 1.2 %; see Table 2).
Participants were slightly more likely to be screened
for GDM (95.6 % versus 93.1 %). Overall, participants
and non-participants were very similar in their behav-
ioral risk factors assessed on the Early Start Question-
naire at the first prenatal visit (Table 3). Participants
and non-participants did not differ in terms of smoking
during the 12 months before pregnancy or during
pregnancy. However, participants were slightly more
likely to report drinking alcohol both before pregnancy
(Table 3).
The use of RPGEH Pregnancy Cohort specimens and
data are governed by the guiding principles of use and
access established by the RPGEH. These principles in-
clude: 1) promote good science for the benefit of the
public; 2) protect participant confidentiality and priv-
acy; honor commitments made to participants and act
within the scope of their consent; and preserve the
trust that KPNC members have in KPNC; 3) comply
with applicable legal and regulatory requirements; 4) con-
sider whether the Resource is the best or only resource to
address proposed research questions; 5) conserve limited
materials or resources for high-value research, such as
biospecimens, which can be exhausted, and use of bios-
pecimens that are rare or of higher value because of
the data associated with them; 6) ensure that an investi-
gator at the KPNC Division of Research (DOR) is in-
volved in the research question and the conduct of the
study to ensure the right and appropriate use of the
Table 1 Characteristics of RPGEH Prenatal Cohort Participants











18–24 14,590 (15.6) 2,456 (15.1) 12,134 (15.9)
25–29 25,685 (27.5) 4,769 (28.1) 20,916 (27.4)
30–34 32,469 (34.8) 6,158 (36.3) 26,311 (34.4)
35–39 16,574 (17.7) 2,940 (17.9) 13,634 (17.8)
40 or older 4,065 (4.4) 653 (3.8) 3,412 (4.5)
Unknown 26 (<0.1) 1 (<0.1) 25 (<0.1)
Race/Ethnicity
Non-Hispanic White 36,704 (39.3) 7,975 (47.0) 28,729 (37.6)
Hispanic 22,578 (24.2) 3,909 (23.0) 18,669 (24.4)
Asian 22,413 (24.0) 3,264 (19.2) 19,149 (25.0)
African American 6,448 (6.9) 960 (5.6) 5,488 (7.2)
Other 3,965 (4.2) 691 (4.1) 3,274 (4.3)
Unknown 1,301 (1.4) 178 (1.1) 1,123 (1.5)
Parity
0 58,395 (62.5) 10,312 (60.7) 48,083 (62.9)
1 26,210 (28.1) 5,030 (29.6) 21,180 (27.7)
2+ 8,804 (9.4) 1,635 (9.6) 7,169 (9.4)
Pre-pregnancy BMI (kg/m2)
< 18.5 1919 (2.4) 276 (1.9) 1,643 (2.5)
18.5–24.9 36,957 (46.2) 6,607 (44.8) 30,350 (46.5)
25.0–29.9 20, 758 (25.9) 4,013 (27.2) 16,745 (25.6)
30.0+ 17,132 (21.4) 3546 (24.0) 13,586 (20.8)
Unknown 3,320 (4.2) 315 (2.1) 3,005 (4.6)
Gestational age at initiation of prenatal care
1st trimester 83,551 (89.5) 16,041 (94.5) 67,510 (88.3)
2nd trimester 6,707 (7.2) 722 (4.3) 5,985 (7.8)
3rd trimester 2,980 (3.2) 141 (0.8) 2,839 (3.7)




8.9 (8.6) 10.0 (9.1) 8.6 (8.5)
Length of enrollment
after pregnancy (years)
2.5 (1.2) 2.7 (1.3) 2.5 (1.2)
aAge at standard first trimester prenatal panel blood draw
Hedderson et al. BMC Pregnancy and Childbirth  (2016) 16:381 Page 6 of 10
resources. Applications for use of RPGEH Pregnancy
Cohort samples and data are submitted and reviewed
by the RPGEH Access Review Committee (ARC). The
ARC meets three times a year to review applications
for use of RPGEH data and specimens. The ARC in-
cludes DOR investigators, plus external stakeholders
and investigators to address specific content and meth-
odological issues as required by the projects under con-
sideration. The ARC governs access to and use of all
RPGEH data and specimens by requestors.
Applications for access will be subject to three phases
of review, and the ARC’s decisions are made based on a
formalized set of criteria that can be reviewed.
Statistical analyses, power and sample size considerations
Based on our expected cohort size of 25,000 women we
computed power for hypothetical case-control studies.
We assumed all available cases will be included and con-
trols will be sampled at a ratio of 5:1. We computed the
minimum detectable odds ratio (OR) for a two-sided test
at level 0.05 and 80 % power for several outcomes with
different prevalences. For the outcome of small for ges-
tational age (prevalence 9.3 %) a case-control study will
be powered to detect an OR of 1.15. For the outcome of
gestational hypertension (prevalence 4.1 %) a case-
control study will be powered to detect an OR of 1.22.
For the rare outcome of very low birthweight (preva-
lence 0.7 %) a case-control study will be powered to de-
tect an OR of 1.57.
Discussion
This report provides a brief overview of the establish-
ment of the KPNC RPGEH Pregnancy Cohort and its
biorepository, which were created to provide a resource
Table 2 Perinatal Outcomes of the RPGEH Prenatal Cohort









Perinatal Outcome N (%)
Preeclampsia
None 71,368 (89.1) 13,017 (88.2) 58,315 (89.3)
Pre-existing
hypertension
2,441 (3.1) 524 (3.4) 1,917 (2.9)
Gestational
hypertension
3,079 (3.8) 604 (4.1) 2,475 (3.8)
Preeclampsia/
Eclampsia
3,198 (4.0) 612 (4.1) 2,586 (4.0)
Glucose Tolerance Status
Normal Screening 56,461 (70.5) 10,861 (73.6) 45,599 (69.8)
Abnormal Screening 12,013 (15.0) 2,125 (14.4) 9,930 (15.2)
Gestational Diabetes 5,366 (6.7) 959 (6.5) 4,508 (6.9)
Preexisting T2DM 961 (1.2) 162 (1.1) 784 (1.2)
Not Screened 4,805 (6.4) 649 (4.4) 4,508 (6.9)
Gestational Age
< 37 weeks 6,063 (7.6) 1,095 (7.4) 4,968 (7.6)
≥ 37 weeks 74,005 (92.4) 13,662 (92.6) 60,343 (92.4)




324 (0.4) 57 (0.4) 267 (0.4)
Severe Preterm
(28–31 week)
526 (0.7) 91 (0.6) 435 (0.7)
Moderate Preterm
(32–33 weeks)
698 (0.9) 116 (0.8) 582 (0.9)
Late Preterm
(34–36 weeks)
4,515 (5.6) 831 (5.6) 3,684 (5.6)
≥ 37 weeks 74,005 (92.4) 13,662 (92.6) 60,343 (92.4)
Unknown 18 (<0.1) 0 (0) 18 (<0.1)
Gestational weight gain in relation to the IOM weight gain guidelines
Below 10,456 (13.1) 1,847 (12.5) 8,609 (13.2)
Met 17,196 (21.5) 3,115 (21.1) 14,081 (21.6)
Exceeded 48,689 (60.8) 9,416 (63.8) 39,273 (60.1)
Unknown 3,745 (4.7) 379 (2.6) 3,366 (5.2)
Infant birth weight
(grams)a
3,361 ± 556 3,400 ± 565 3,350 ± 553
AGA 63,843 (81.4) 11,771 (81.3) 52,072 (81.4)
SGA 7,436 (9.5) 1,339 (9.3) 6,097 (9.5)
LGA 6,992 (8.9) 1,342 (9.3) 5,650 (8.8)
Unknown 135 (0.2) 17 (0.1) 118 (0.2)
Infant birth weight (grams)
Very low birth weight
(<1,500)
605 (0.8) 106 (0.7) 499 (0.8)
Table 2 Perinatal Outcomes of the RPGEH Prenatal Cohort




3,158 (4.0) 555 (3.8) 2,603 (4.1)
Normal birth weight
(2,501–3,999)
65,975 (84.2) 12,042 (83.2) 53,933 (84.4)
Macrosomia (4,000+) 8,582 (10.9) 1,757 (12.2) 6,825 (10.7)
Unknown 86 (0.1) 9 (0.1) 77 (0.1)
NICU Stay
Non-NICU 71,563 (89.4) 13,092 (88.7) 58,471 (89.5)
NICU 8,393 (10.5) 1,647 (11.2) 6,746 (10.3)
Delivery room death 112 (0.1) 17 (0.1) 95 (0.2)
Unknown 18 (<0.1) 1 (<0.1) 17 (<0.1)
aLGA is large-for-gestational age, adjusted for race/ethnicity
SGA is small-for-gestational age, adjusted for race/ethnicity
AGA is appropriate for-gestational age, adjusted for race/ethnicity
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for women’s and children’s health research. The KPNC
RPGEH Pregnancy Cohort is uniquely integrated into
routine clinical prenatal care within the KPNC health
care system setting and can be linked with data from
the EHR. KPNC contains a racially and ethnically diverse
population, thereby increasing the likelihood of obtaining
a highly representative sample with generalizable findings.
The establishment of this valuable resource has the po-
tential to address many key questions related to women’s
and children’s health and is particularly timely, in light of
the recent dissolution of The National Children’s Study.
The National Children’s Study (NCS) was developed after
a 1990s White House Task Force highlighted the paucity
of evidence evaluating the links between environmental
exposures, development, and health outcomes in children
and adults. The Children’s Health Act of 2000 initiated
the conduct of a national longitudinal study of environ-
mental influences (including physical, chemical, biological,
and psychosocial) during pregnancy on child health and
development. A recent report explains that this study was
dissolved due to feasibility and oversight issues [21, 22]
and suggests that funding agencies support smaller fo-
cused studies designed as tailored explorations as well as
cohorts to facilitate longitudinal biospecimen collection
and banking.
This large pregnancy cohort, derived from a diverse base
population, can be used to generate sets of cases and con-
trols for future clinical research studies, as demonstrated
by our preliminary data. The availability of rich clinical
data from the EHR, the questionnaire data, and existing
perinatal research programs provide detailed phenotypic
information that will further facilitate the conduct of peri-
natal epidemiology and translational studies. The RPGEH
Pregnancy Cohort, coupled with the state of the art KPNC
Biorepository for long-term storage of serum, plasma and
DNA samples and an ability to follow both women and
their child long term for future health outcomes in the
EHR, provides a truly unique and valuable resource for
improving our understanding of women and children’s
health.
Table 3 Substance use before and during pregnancy among
RPGEH Prenatal Cohort Participants compared to Non-








Early Start Data N (%)
Smoking in 12 Months before Pregnancy
Never 78,710 (89.5) 14,683 (88.5) 64,027 (89.7)
Monthly or Less 2,944 (3.4) 623 (3.8) 2,321 (3.3)
Weekly 1,304 (1.5) 230 (1.4) 1,074 (1.5)
Daily 4,747 (5.4) 1,016 (6.1) 3,731 (5.2)
Unknown 223 (0.2) 32 (0.2) 191 (0.3)
Smoking since Pregnancy
Never 85,166 (96.9) 16,010 (96.5) 69,156 (96.9)
Monthly or Less 789 (0.9) 159 (1.0) 630 (0.9)
Weekly 537 (0.6) 117 (0.7) 420 (0.6)
Daily 1,196 (1.3) 267 (1.6) 929 (1.3)
Unknown 240 (0.3) 31 (0.2) 209 (0.3)
Alcohol in 12 Months before Pregnancy
Never 28,267 (32.2) 4,202 (25.3) 24,065 (33.7)
Monthly or less 39,589 (45.0) 7,908 (47.7) 31,681 (44.4)
Weekly 18,102 (20.6) 4,058 (24.5) 14,044 (19.7)
Daily 1,429 (1.6) 327 (2.0) 1,102 (1.6)
Unknown 541 (0.6) 89 (0.5) 452 (0.6)
Alcohol since Pregnancy
Never 78,796 (89.6) 14,551 (87.7) 64,245 (90.1)
Monthly or Less 6,780 (7.7) 1,517 (9.2) 5,263 (7.3)
Weekly 1,423 (1.6) 344 (2.1) 1,079 (1.5)
Daily 179 (0.2) 34 (0.2) 145 (0.2)
Unknown 750 (0.9) 138 (0.8) 612 (0.9)
Use of Prescription Drug in 12 Months before Pregnancya
No 71,212 (81.0) 13,067 (78.8) 58,145 (81.5)
Yes 16,066 (18.3) 3,403 (20.5) 12,663 (17.7)
Unknown 650 (0.7) 114 (0.7) 536 (0.8)
Use of Prescription Drug since Pregnancy
No 83,680 (95.2) 15,726 (94.8) 67,954 (95.3)
Yes 3,871 (4.4) 799 (4.8) 3,072 (4.3)
Unknown 377 (0.4) 59 (0.4) 318 (0.4)
Use of Illegal Drug in 12 Months before Pregnancyb
No 79,954 (90.9) 14,790 (89.1) 65,164 (91.3)
Yes 7,149 (8.1) 1,506 (9.1) 5,643 (7.9)
Unknown 825 (1.0) 288 (1.8) 537 (0.8)
Table 3 Substance use before and during pregnancy among
RPGEH Prenatal Cohort Participants compared to Non-
Participants in Kaiser Permanente Northern California
(Continued)
Use of Illegal Drug since Pregnancy
No 85,202 (96.9) 15,878 (95.7) 69,324 (97.2)
Yes 2,033 (2.3) 414 (2.5) 1,619 (2.3)
Unknown 693 (0.8) 292 (1.8) 401 (0.5)
aPrescription drugs in Early Start data include anxiety medications, pain
medications, and sleep medications
bIllegal drugs in Early Start data include Cocaine, Heroin, Marijuana,
and Methamphetamines
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Our preliminary data on the RPGEH Pregnancy Cohort
demonstrate that at least 18.2 % of pregnant women par-
ticipated, and the cohort is highly representative of the
underlying KPNC pregnant population in terms of both
maternal demographics and key perinatal outcomes. Preg-
nancy cohort participants were KNPC members on aver-
age 10 years before their index pregnancy and remained
members on average 2.7 years after pregnancy to date,
and most are still currently KPNC members. Thus,
there is a unique ability to examine exposures even
years before pregnancy and to follow women and their
infants for years after delivery. While participating
women were slightly more likely to be non-Hispanic
white and less likely to be Asian, this pattern is fre-
quently observed in cohort studies with multiethnic
populations such as KPNC women of reproductive age.
Overall, the RPGEH Pregnancy Cohort is extremely di-
verse, with 53 % of participants from non-white racial
ethnic minority groups, and Asian women comprise
23 % of the cohort. This is especially significant as
Asian women have previously been reported as less
likely to participate in reproductive and biospecimen
research [22, 23]. The racial-ethnic diversity of this
population provides important potential for studies
examining racial-ethnic disparities in diseases and
health care delivery. Given the recruitment efforts inte-
gration within clinical care, it is possible that not all
pregnant women at participating medical facilities were
invited to participate in the pregnancy cohort; there-
fore, 18.2 % is likely an underestimate of the overall
participation rate.
The prevalence of several perinatal complications was
similar between RPGEH cohort participants and the
underlying populations of women delivering in KPNC.
Cohort participants were slightly less likely to have gesta-
tional diabetes mellitus (GDM) and infants of participants
were slightly more likely to be macrosomic relative to
non-participants. The lower prevalence of GDM among
RPGEH participants is probably due in part to the fact
that participants were less likely to be Asian and more
likely to be non-Hispanic white; in this setting, Asian
woman have the highest prevalence of GDM [15, 24]
and non-Hispanic white women have the lowest preva-
lence of GDM.
The fetal origins of adult disease hypothesis posits
that “fetal programming” occurs when maternal meta-
bolic nutrition, environment and hormonal milieu dur-
ing development permanently programs the structure
and physiology of organs and hence the future health of
the offspring [25]. While there is some epidemiologic
evidence supporting the “fetal programming” hypoth-
esis, more longitudinal, observational studies examining
the effects of a broad range of environmental and bio-
logical factors assessed in utero are needed to clarify the
extent to which fetal programming contributes to adult
diseases. In addition, a woman’s health status during preg-
nancy may also influence her future health [26]. For ex-
ample, women diagnosed with pregnancy-related
hypertension and/or preeclampsia, gestational diabetes
and preterm birth are at higher risk for hypertension,
diabetes and cardiovascular disease later in life [7].
Therefore, given the rich health data in the KPNC
EHR, the RPGEH Pregnancy Cohort will also allow for
a lifecourse research approach [27].
The resource is available to be used by Kaiser Perma-
nente researchers as well as outside investigators who
wish to collaborate with a Kaiser Permanente researcher
to conduct biomarker, genetic, environmental and gene
environment interaction studies. The RPGEH Pregnancy
Cohort has the unique ability to connect biospecimens
collected at two time points during pregnancy with de-
tailed short- and long-term environmental and clinical
data on both women and their children, enabling research
of immediate perinatal complications as well as longer
term maternal, child, and adult outcomes.
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